Skip to main navigation
Skip to search
Skip to main content
MD Anderson Cancer Center Home
Help & FAQ
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Search by expertise, name or affiliation
View Scopus Profile
Yue Wei
Assistant Professor
Leukemia
https://orcid.org/0000-0002-2288-8405
h-index
3504
Citations
27
h-index
Calculated based on number of publications stored in Pure and citations from Scopus
2000
2024
Research activity per year
Overview
Fingerprint
Network
Research output
(54)
Similar Profiles
(6)
Fingerprint
Dive into the research topics where Yue Wei is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Myelodysplastic Syndrome
94%
Chronic Myeloid Leukemia
42%
Overexpression
33%
Hypomethylating Agents
29%
Acute Myeloid Leukemia
22%
Leukemia Cell Lines
20%
CD34+ Cells
16%
Deregulation
15%
Hematopoietic Stem Cells
14%
KDM6B
13%
GX15-070
12%
Innate Immune Signaling
12%
Toll-like
12%
Hematopoiesis
11%
Decitabine
10%
Therapeutic Target
9%
Apoptosis
9%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
9%
Differential Expression
8%
Histone Modification
8%
Vorinostat
8%
Gene Expression
8%
Promoter Methylation
8%
Innate Immunity
8%
Receptor Signaling
8%
Azacitidine
8%
Histone Deacetylase Inhibitor (HDACi)
8%
Hematopoietic Differentiation
7%
Human Leukemia
7%
Myeloid Neoplasms
7%
Programmed Death-ligand 1 (PD-L1)
7%
Tet Methylcytosine Dioxygenase 2
7%
Genetic Mapping
7%
JMJD3
7%
Leukemia Patients
6%
Bone Marrow
6%
Post-translational Modification
6%
IMPDH
6%
Histone Transcription
6%
Body Components
6%
Transcriptomic Signature
6%
MiR-125b
6%
Monopoiesis
6%
SF3B1 mutation
6%
Syndrome-based
6%
Body Maintenance
6%
Quantitative Proteomic Analysis
6%
Ruxolitinib
6%
5-hydroxymethylcytosine (5hmC)
6%
Hematologic Improvement
6%
Biochemistry, Genetics and Molecular Biology
Myeloid
37%
Cyclin E
28%
S Phase
27%
Hematopoietic Cell
25%
Histone H4
20%
Cajal Body
20%
Hematopoiesis
19%
Promoter Region
19%
Histone
19%
Histone Gene
18%
Cytogenetics
17%
CD34
16%
Cell Cycle
16%
Overall Survival
15%
Decitabine
14%
Gene Expression
13%
Transcription
12%
Innate Immunity
10%
Complement Factor B
9%
Genetics
8%
Immunity
8%
Platelet
8%
Gene Expression Profiling
8%
Transcription Factor
7%
Genetic Transcription
7%
Histone Modification
7%
Epigenetics
7%
Quantitative Proteomics
6%
Cyclin-Dependent Kinase
6%
CYP1B1
6%
RIPK1
6%
Clinical Trial
6%
Optical Genome Mapping
6%
Transcriptomics
6%
Somatic Cell
6%
Histone Deacetylase
6%
EZH2
6%
Sample Size
6%
Posttranslational Modification
6%
Necroptosis
6%
SF3B1
6%
LILRB4
6%
STAT3
6%
CTLA-4
6%
Hemocyte
6%
Gene Control
6%
Gene Mapping
6%
Cooperation
6%
Downregulation
6%
CpG Island
6%
Medicine and Dentistry
Myelodysplastic Syndrome
100%
Chronic Myelomonocytic Leukemia
32%
Hypomethylating Agent
30%
Acute Myeloid Leukemia
22%
Hematopoietic Cell
22%
Hematopoiesis
17%
Leukemia Cell Line
14%
Immunity
14%
CTLA-4
12%
Overall Survival
11%
Leukemia
11%
Nuclear Factor
9%
Promoter Region
9%
Acute Lymphoblastic Leukemia
9%
Gene Expression
8%
Histone Deacetylase Inhibitor
8%
Toll Like Receptor
7%
Azacitidine
7%
Vorinostat
7%
Gene Expression Profiling
7%
Blood Cell
6%
Cooperation
6%
Notch
6%
Ruxolitinib
6%
Clinical Trial
6%
Programmed Death 1 Ligand 1
6%
Optical Genome Mapping
6%
Antiinflammatory Activity
6%
Transcriptomics
6%
Histone Deacetylase
6%
Histone Methylation
6%
Necroptosis
6%
Bortezomib
6%
Isothiocyanic Acid
6%
Gene Mutation
6%
Acute B-Cell Lymphoblastic Leukemia
6%
Disease Exacerbation
6%
Diseases
6%
Decitabine
5%
Myeloid Malignancy
5%
